利伐沙班治疗心房颤动合并稳定性冠心病的临床疗效观察  

Clinical Observation of Rivaroxaban in the Treatment of Atrial Fibrillation with Stable Coronary Heart Disease

作　　者：谷新胜 何悦[1] 赵莉芳[1] 陈小妮 高迪 郑宏超[1] GU Xinsheng;HE Yue;ZHAO Lifang;CHEN Xiaoni;GAO Di;ZHENG Hongchao(Shanghai Xuhui District Central Hospital,Shanghai 200031,China)

机构地区：[1]上海市徐汇区中心医院,200031

出　　处：《实用心脑肺血管病杂志》2020年第S02期117-119,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察分析利伐沙班治疗心房颤动合并稳定性冠心病的临床疗效。方法选取2019年2月—2020年6月上海市徐汇区中心医院收治的100例心房颤动合并稳定性冠心病患者作为本次的研究对象,随机分为研究组与参照组,每组50例。参照组实施华法林治疗方案,研究组实施利伐沙班治疗方案,比较两组患者脑栓塞、脑出血发生情况和治疗前后的国际标准化比值水平与治疗后国际标准化比值达标情况。结果研究组患者脑栓塞发生率为4.00%,低于参照组的8.00%,差异无统计学意义(P>0.05);研究组患者脑出血发生率为2.00%,明显低于参照组患者的20.00%,比较差异有统计学意义(P<0.05)。在治疗前,两组患者国际标准化比值水平无明显差异,比较差异无统计学意义(P>0.05);在治疗后,研究组患者国际标准化比值水平明显优于参照组,研究组患者国际标准化比值达标率明显高于参照组,比较差异有统计学意义(P<0.05)。结论在治疗心房颤动合并稳定性冠心病的过程中采用利伐沙班治疗方案能够取得良好的临床疗效,且脑出血的发生率明显降低,值得临床推广应用。Objective To observe and analyze the clinical efficacy of rivaroxaban in the treatment of atrial fibrillation complicated with stable coronary heart disease.Methods 100 patients with atrial fibrillation complicated with stable coronary heart disease in the hospital from February 2019 to June 2020 were selected and randomly divided into study group and reference group,50 cases in each group.The control group was treated with warfarin,and the study group was treated with rivaroxaban.The incidence of cerebral embolism and cerebral hemorrhage,and the level of international standardized ratio before and after treatment were compared between the two groups.Results The incidence of cerebral embolism in the study group was 4.00%,whichwas lower than 8.00%of the reference group,the data difference was not statistically significant(P>0.05).The incidence of cerebral hemorrhage in the study group was 2.00%,whichwas significantly lower than 20.00%of the reference group,with statistically significant difference(P<0.05).Before treatment,there was no significant difference in the level of international standardized ratio between the two groups,with no statistically significant difference(P>0.05);after treatment,the level of international standardized ratio in the study group was significantly better than that in the reference group,and the compliance rate of the international standardized ratio in the study group was significantly higher than that in the reference group,with statistically significant difference(P<0.05).Conclusion In the treatment of atrial fibrillation with stable coronary heart disease,rivaroxaban treatment can achieve good clinical efficacy,and the incidence of cerebral hemorrhage is significantly reduced,which is worthy of clinical application.

关 键 词：利伐沙班 心房颤动 稳定性冠心病 临床疗效 

分 类 号：R541.4[医药卫生—心血管疾病] R541.75[医药卫生—内科学]